Neumora Therapeutics (NMRA) Treasury Shares (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Treasury Shares of $435000.0 for Q1 2026, up 291.89% year-over-year from $111000.0 in Q1 2025, and down 34.29% quarter-over-quarter from $662000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Treasury Shares (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Treasury Shares history runs 5 years deep, the most recent figure standing at $435000.0 for Q1 2026.
- In Q1 2026, Treasury Shares rose 291.89% year-over-year to $435000.0; the TTM figure through Mar 2026 stood at $435000.0 (up 291.89% YoY), while the FY2025 annual figure was $662000.0, up 78.44% from the prior year.
- Treasury Shares for Q1 2026 stood at $435000.0, down from $662000.0 in the prior quarter.
- The five-year high for Treasury Shares was $104.4 million in Q4 2022, with the low at $111000.0 in Q1 2025.
- The 5-year median for Treasury Shares is $1.5 million (2024), against an average of $28.3 million.
- The sharpest annual moves came in 2023 and 2026: Treasury Shares plunged 99.2% in 2023, then soared 291.89% in 2026.
- Neumora Therapeutics' Treasury Shares stood at $104.4 million in 2022, then slumped by 99.2% to $840000.0 in 2023, then sank by 55.83% to $371000.0 in 2024, then jumped by 78.44% to $662000.0 in 2025, then sank by 34.29% to $435000.0 in 2026.
- Business Quant data shows NMRA's Treasury Shares at $435000.0 in Q1 2026, $662000.0 in Q4 2025, and $662000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 435,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435,000.00 |
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | 662,000.00 |
| Dec 31, 2025 | 662,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 840,000.00 |
| Dec 31, 2023 | 840,000.00 |